• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT-2 inhibitors in cancer patients with diabetes: when cardioprotection is key.

作者信息

Brambilla Mattia, Larroux Bianca, Bonaventura Aldo

机构信息

Internal Medicine Residency Program, School of Medicine, University of Insubria, Via Ottorino Rossi 9, 21100 Varese, Italy.

Medical Center, S.C. Medicina Generale 1, Department of Internal Medicine, Ospedale di Circolo and Fondazione Macchi, ASST Sette Laghi, Viale Borri 57, 21100 Varese, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):353-355. doi: 10.1093/ehjcvp/pvaf038.

DOI:10.1093/ehjcvp/pvaf038
PMID:40398924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12231135/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ecf/12231135/478c220cf220/pvaf038f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ecf/12231135/478c220cf220/pvaf038f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ecf/12231135/478c220cf220/pvaf038f1.jpg

相似文献

1
SGLT-2 inhibitors in cancer patients with diabetes: when cardioprotection is key.糖尿病癌症患者中的钠-葡萄糖协同转运蛋白2抑制剂：心脏保护为何至关重要。
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):353-355. doi: 10.1093/ehjcvp/pvaf038.
2
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
3
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.SGLT-2 抑制剂与 GLP-1 受体激动剂在 2 型糖尿病合并慢性肾脏病患者中的心血管和肾脏结局：系统评价和网络荟萃分析。
Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z.
4
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.每周一次司美格鲁肽与 SGLT-2 抑制剂在二甲双胍单药治疗控制不佳的 2 型糖尿病患者中的疗效比较：系统文献回顾和网络荟萃分析。
Curr Med Res Opin. 2018 Sep;34(9):1595-1603. doi: 10.1080/03007995.2018.1476332. Epub 2018 May 29.
5
Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients-A Narrative Review.非糖尿病患者中与SGLT-2抑制剂相关的正常血糖性酮症酸中毒——一篇叙述性综述
J Gen Intern Med. 2025 Feb;40(2):437-442. doi: 10.1007/s11606-024-09073-2. Epub 2024 Oct 1.
6
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.2 型糖尿病血糖控制安全性和疗效的系统评价和网络荟萃分析。
PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. eCollection 2019.
7
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂治疗慢性肾脏病成人患者：临床实践指南。
BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257.
8
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.二肽基肽酶-4（DPP-4）抑制剂或钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂联合二甲双胍治疗 2 型糖尿病患者的安全性：系统评价和荟萃分析。
Diabetes Metab Res Rev. 2014 May;30(4):269-83. doi: 10.1002/dmrr.2494.
9
Secular trends in the utility of SGLT-2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland.昆士兰东南部麦德洛南区卫生服务中心各医院2型糖尿病心力衰竭患者中SGLT-2抑制剂使用情况的长期趋势。
Intern Med J. 2023 Nov;53(11):2085-2092. doi: 10.1111/imj.15993. Epub 2022 Dec 30.
10
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.钠葡萄糖协同转运蛋白2（SGLT2）抑制剂与二肽基肽酶-4（DPP-4）抑制剂及2型糖尿病患者发生心房颤动的风险：一项荟萃分析。
BMC Cardiovasc Disord. 2025 Jan 28;25(1):59. doi: 10.1186/s12872-024-04442-5.

本文引用的文献

1
Effects of SGLT2 Inhibitors in Patients with Cancer and Diabetes Mellitus: A Systematic Review and Meta-analysis.SGLT2抑制剂对癌症合并糖尿病患者的影响：一项系统评价与Meta分析
Eur Heart J Cardiovasc Pharmacother. 2025 Apr 25. doi: 10.1093/ehjcvp/pvaf028.
2
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对癌症患者及幸存者心力衰竭结局的影响：一项系统评价和荟萃分析。
Eur J Prev Cardiol. 2025 Mar 6. doi: 10.1093/eurjpc/zwaf026.
3
Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis.
钠-葡萄糖协同转运蛋白2抑制剂与转甲状腺素蛋白淀粉样心肌病的预后：系统评价与荟萃分析
Eur J Clin Invest. 2025 Jun;55(6):e14392. doi: 10.1111/eci.14392. Epub 2025 Jan 27.
4
SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病患者癌症治疗相关心脏功能障碍的一级预防
JACC CardioOncol. 2024 Sep 22;6(6):863-875. doi: 10.1016/j.jaccao.2024.08.001. eCollection 2024 Dec.
5
Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.恩格列净用于预防心脏毒性：恩格列净预防心脏毒性试验（EMPACARD - PILOT）
Cardiooncology. 2024 Sep 5;10(1):58. doi: 10.1186/s40959-024-00260-y.
6
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: State-of-the-Art Review.钠-葡萄糖协同转运蛋白2抑制剂的心脏保护和抗癌作用：最新综述
JACC CardioOncol. 2024 Mar 12;6(2):159-182. doi: 10.1016/j.jaccao.2024.01.007. eCollection 2024 Apr.
7
Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis.2型糖尿病合并癌症患者中与钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗相关的心血管结局：一项系统评价和荟萃分析
Diabetol Metab Syndr. 2024 May 22;16(1):108. doi: 10.1186/s13098-024-01354-4.
8
Dutch cardio-oncology cohort: Incident cardiovascular disease predisposes to a higher cancer mortality rate.荷兰心脏肿瘤队列研究：新发心血管疾病易导致更高的癌症死亡率。
Eur J Clin Invest. 2024 Sep;54(9):e14255. doi: 10.1111/eci.14255. Epub 2024 May 17.
9
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.钠-葡萄糖共转运蛋白 2 抑制剂在癌症治疗相关心脏功能障碍患者中的应用与临床事件风险。
JACC Heart Fail. 2024 Jan;12(1):67-78. doi: 10.1016/j.jchf.2023.08.026. Epub 2023 Oct 25.
10
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.